← All CTA Flashcard Decks

Study Startup & Feasibility Flashcards

7 cards from real CTA practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.

Read the first 7 Study Startup & Feasibility flashcards as text
  1. A site's IRB approval expires during the study startup phase before the first subject is enrolled. What must happen before enrollment can begin?

    Answer: The IRB approval must be renewed and documented before any subject is enrolled

    Enrollment cannot begin under an expired IRB approval; the site must obtain current IRB approval regardless of how close expiration was to the start date.

  2. During a site evaluation, the CTA learns the investigator plans to delegate the informed consent process entirely to a research assistant with no medical training. What is the MOST appropriate response?

    Answer: Flag the delegation as non-compliant because consent must be obtained by a qualified person as defined by local regulations

    Informed consent must be obtained by individuals qualified to answer subject questions about the study — typically clinically trained personnel — as required by ICH E6 and local regulations.

  3. Which startup document defines the specific tasks assigned to each member of the study team at the site?

    Answer: Delegation of Authority Log

    The Delegation of Authority Log lists each team member and the specific protocol-related tasks they are authorized to perform.

  4. A CTA is assessing a site's patient database for recruitment potential. The database contains 500 patients with the target condition, but the protocol requires a washout of 6 months from a commonly used concomitant medication. After applying this criterion, only 60 patients remain. This scenario BEST illustrates the importance of:

    Answer: Applying all eligibility criteria when estimating actual recruitment potential

    Gross patient counts can be misleading; realistic recruitment estimates require applying all inclusion/exclusion criteria to the database.

  5. A sponsor sends the first shipment of investigational medicinal product (IMP) to a site that has not yet received IRB approval. According to GCP, what should the site do?

    Answer: Accept the shipment but quarantine it with a 'do not use' label

    While returning is ideal, quarantining the IMP with a clear 'do not use' label until regulatory approval is received is an acceptable GCP-compliant practice endorsed by many sponsors.

  6. What is the primary reason sponsors conduct a competitive landscape analysis during feasibility?

    Answer: To understand whether competing trials may limit patient availability at target sites

    Competing trials enrolling the same patient population can significantly reduce available subjects and slow recruitment at a given site.

  7. Which element is LEAST likely to be verified during a Site Initiation Visit (SIV)?

    Answer: The investigator's personal tax filing status

    An investigator's personal tax status is a personal financial matter unrelated to site qualification or study conduct.